Delineating selective vulnerability of inhibitory interneurons in Alpers' syndrome
Open Access
- 19 July 2022
- journal article
- research article
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 48 (6) , e12833
Abstract
Aims: Alpers' syndrome is a severe neurodegenerative disease typically caused by bi‐allelic variants in the mitochondrial DNA (mtDNA) polymerase gene, POLG, leading to mtDNA depletion. Intractable epilepsy, often with an occipital focus, and extensive neurodegeneration are prominent features of Alpers' syndrome. Mitochondrial oxidative phosphorylation (OXPHOS) is severely impaired with mtDNA depletion and is likely to be a major contributor to the epilepsy and neurodegeneration in Alpers' syndrome. We hypothesised that parvalbumin‐positive(+) interneurons, a neuronal class critical for inhibitory regulation of physiological cortical rhythms, would be particularly vulnerable in Alpers' syndrome due to the excessive energy demands necessary to sustain their fast‐spiking activity.Methods: We performed a quantitative neuropathological investigation of inhibitory interneuron subtypes (parvalbumin+, calretinin+, calbindin+, somatostatin interneurons+) in postmortem neocortex from 14 Alpers' syndrome patients, five sudden unexpected death in epilepsy (SUDEP) patients (to control for effects of epilepsy) and nine controls.Results: We identified a severe loss of parvalbumin+ interneurons and clear evidence of OXPHOS impairment in those that remained. Comparison of regional abundance of interneuron subtypes in control tissues demonstrated enrichment of parvalbumin+ interneurons in the occipital cortex, while other subtypes did not exhibit such topographic specificity.Conclusions: These findings suggest that the vulnerability of parvalbumin+ interneurons to OXPHOS deficits coupled with the high abundance of parvalbumin+ interneurons in the occipital cortex is a key factor in the aetiology of the occipital‐predominant epilepsy that characterises Alpers' syndrome. These findings provide novel insights into Alpers' syndrome neuropathology, with important implications for the development of preclinical models and disease‐modifying therapeutics.Keywords
Funding Information
- Wellcome Trust Centre for Mitochondrial Research (203105/Z/16/Z)
- Medical Research Council (G0400074)
This publication has 64 references indexed in Scilit:
- New insights into the classification and nomenclature of cortical GABAergic interneuronsNature Reviews Neuroscience, 2013
- Microangiopathy in the cerebellum of patients with mitochondrial DNA diseaseBrain, 2012
- Cerebellar Ataxia in Patients With Mitochondrial DNA DiseaseJournal of Neuropathology & Experimental Neurology, 2012
- The Energy Demand of Fast Neuronal Network Oscillations: Insights from Brain Slice PreparationsFrontiers in Pharmacology, 2012
- Sensory neuronopathy in patients harbouring recessive polymerase γ mutationsBrain, 2011
- Loss and reorganization of calretinin-containing interneurons in the epileptic human hippocampusBrain, 2010
- Status epilepticus in children with Alpers’ disease caused byPOLG1mutations: EEG and MRI featuresEpilepsia, 2009
- Developmental expression of the Ca2+‐binding proteins calretinin and parvalbumin at the calyx of Held of rats and miceEuropean Journal of Neuroscience, 2004
- Free Radical–Mediated Cell Damage After Experimental Status Epilepticus in Hippocampal Slice CulturesJournal of Neurophysiology, 2002
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990